Lipoprotein(a), abbreviated Lp(a) and pronounced “L-P-little-A,” is a cholesterol-carrying particle whose concentration is determined mainly by genetics. High Lp(a) can increase the risk of atherosclerotic cardiovascular disease, including heart attack and ischemic stroke, and is also associated with calcific aortic valve stenosis. Unlike ordinary LDL cholesterol, Lp(a) usually changes very little with diet, exercise or weight loss. The 2026 American College of Cardiology and American Heart Association dyslipidemia guideline recommends that every adult have Lp(a) measured at least once. A concentration of 125 nmol/L or higher, or approximately 50 mg/dL or higher when measured using mass-based methods, is considered an important cardiovascular risk-enhancing factor. Although lifestyle changes generally do not substantially lower Lp(a) itself, improving LDL cholesterol, blood pressure, metabolic health and other modifiable risks can help reduce overall cardiovascular risk.

Most people who have their cholesterol checked learn about LDL, HDL and triglycerides. However, a standard cholesterol panel does not usually include lipoprotein(a), even though this inherited marker may help explain cardiovascular disease in some people whose other results appear reasonably favorable.

Someone can have nutritious eating habits, exercise regularly and maintain a healthy body weight while carrying a high Lp(a) concentration throughout life. They may also have normal routine cholesterol results and no noticeable symptoms.

Discovering elevated Lp(a) does not mean a heart attack is inevitable or that arterial plaque has already developed. It means an important risk factor has been identified, allowing a more informed approach to prevention.

That distinction is essential. Lp(a) is not a measure of willpower, dietary discipline or how well someone has followed a health program. Its concentration is mostly inherited.

The appropriate goal is to recognize inherited risk early, protect the cardiovascular system through measures that are within our control and use evidence-based treatment when the overall risk justifies it.

What Exactly Is Lipoprotein(a)?

Lipoprotein(a) is a type of lipoprotein that carries cholesterol and other lipids in the bloodstream. Its structure resembles an LDL particle, but it contains an additional protein that makes it biologically distinct.

Like LDL, Lp(a) contains apolipoprotein B-100, which is a structural protein found on major atherogenic lipoproteins.

What distinguishes Lp(a) is another protein called apolipoprotein(a), or apo(a), attached to the ApoB-containing particle.

The LDL-Like Component

The LDL-like portion of Lp(a) contains cholesterol and other lipids. This component helps explain why Lp(a) can participate in atherosclerotic plaque formation.

Apolipoprotein(a)

Apolipoprotein(a) is a specialized protein whose structure varies considerably among individuals. This variation is influenced by inherited differences in the LPA gene.

Apo(a) contains repeating structural regions called kringles. Differences in the number of these repeated regions contribute to variation in apo(a) size and can influence circulating Lp(a) concentrations.

Why the Additional Protein Matters

The apo(a) component distinguishes Lp(a) from ordinary LDL and is associated with biological characteristics relevant to atherosclerotic and aortic valve disease.

Lp(a) can also carry oxidized phospholipids, which are being investigated for their roles in inflammation and vascular injury.

However, the complete biological function of Lp(a) is not fully understood, and its presence is not required at high concentrations for normal cholesterol transport.

How Is Lipoprotein(a) Different From LDL Cholesterol?

LDL and Lp(a) share important structural features, but they are not interchangeable.

LDL is a major carrier of cholesterol in the bloodstream and is strongly influenced by genetic, dietary and metabolic factors.

Lp(a) contains an LDL-like particle with an additional apo(a) protein, and its concentration is much more strongly determined by inherited variation.

LDL Responds to Several Interventions

LDL cholesterol can often be reduced through changes in dietary fat quality, viscous soluble fiber and established lipid-lowering medication.

The amount of improvement varies, particularly in people with inherited lipid disorders.

Lp(a) Is Primarily Genetic

Most variation in Lp(a) concentration is explained by inherited factors, especially variations involving the LPA gene.

Ordinary dietary and lifestyle changes typically have little effect on the concentration.

Both Can Contribute to Atherosclerosis

LDL and Lp(a) can contribute to the entry and retention of cholesterol-containing particles within artery walls.

Because both are relevant, high Lp(a) may increase risk even when LDL-C is not markedly elevated.

Does LDL Testing Include Lp(a)?

Cholesterol carried by Lp(a) can contribute to the cholesterol reported within LDL-related laboratory measurements.

However, an LDL-C result does not directly reveal the concentration of Lp(a) particles.

Routine attempts to subtract an estimated amount of Lp(a)-cholesterol from LDL-C are generally not recommended because the cholesterol content of Lp(a) particles varies considerably.

A standard LDL cholesterol result cannot replace a specific Lp(a) blood test.

How Is Lp(a) Related to ApoB?

Each Lp(a) particle contains one ApoB-100 molecule. As a result, Lp(a) contributes to the total ApoB concentration measured in blood.

However, most circulating ApoB may come from LDL and other atherogenic lipoproteins rather than Lp(a).

What ApoB Measures

ApoB provides information about the overall concentration of major atherogenic particles, including LDL, VLDL, remnants and Lp(a).

What Lp(a) Measures

An Lp(a) test identifies the concentration of one specific inherited lipoprotein class.

Can ApoB Be Normal When Lp(a) Is High?

Yes. Someone may have an ApoB value that appears reasonably favorable while Lp(a) remains elevated.

Conversely, ApoB may be high because of elevated LDL and other particles even when Lp(a) is low.

These measurements therefore answer different questions and can complement one another when clinically appropriate.

Why Is Lp(a) Mostly Determined by Genetics?

The concentration of Lp(a) is strongly influenced by the LPA gene, which affects the production and characteristics of apolipoprotein(a).

Inherited differences can lead to substantial variation in circulating Lp(a) concentrations among otherwise healthy people.

What Is the Role of the LPA Gene?

The LPA gene contains the instructions for producing apolipoprotein(a).

Variations in this gene affect apo(a) structure and expression, helping determine how much Lp(a) circulates in the bloodstream.

Can You Inherit High Lp(a) From Either Parent?

Yes. Inherited variants from either parent can influence Lp(a) concentration.

Because the genetics are complex, a child does not necessarily have exactly the same Lp(a) level as either parent.

Does High Lp(a) Mean Someone Has a Genetic Disease?

Not necessarily. Elevated Lp(a) is a common inherited cardiovascular risk factor, not automatically a diagnosis of a specific genetic disorder.

It can occur independently or alongside conditions such as familial hypercholesterolemia.

Are Lp(a) Levels the Same Across Populations?

No. Population distributions vary with ancestry, and levels tend to be higher on average in some populations than others.

However, elevated Lp(a) is associated with cardiovascular risk across ancestry groups.

The appropriate clinical response should depend on measured concentration and overall cardiovascular risk, not assumptions based on ancestry alone.

How Common Is High Lipoprotein(a)?

Approximately one in five people worldwide has an elevated Lp(a) concentration according to commonly used risk thresholds.

Many are unaware of it because Lp(a) generally produces no symptoms and is not included automatically in a standard lipid panel.

This makes once-in-adulthood testing particularly valuable. Identifying the marker may lead to earlier prevention, more appropriate lipid-lowering treatment or screening of biological relatives.

How Does High Lp(a) Increase Cardiovascular Risk?

Elevated Lp(a) is associated with an increased lifetime risk of atherosclerotic cardiovascular disease.

Genetic and observational studies support a causal relationship, although the precise biological contributions of different Lp(a) components continue to be investigated.

Atherosclerotic Plaque Formation

Lp(a) particles can enter and become retained within artery walls, contributing cholesterol-rich material to the processes involved in atherosclerosis.

This is one reason elevated Lp(a) is associated with coronary artery disease and ischemic stroke.

Oxidized Phospholipids and Inflammation

Lp(a) can carry oxidized phospholipids that may participate in inflammatory and vascular responses.

These mechanisms are important areas of research, but an Lp(a) blood test does not directly measure the degree of inflammation or arterial injury in an individual.

Blood Clot-Related Biology

Apo(a) has structural similarities to plasminogen, a protein involved in the body's clot-dissolving system.

This has prompted research into possible effects of Lp(a) on thrombosis and fibrinolysis.

However, the exact contribution of these mechanisms to clinical events remains less established than the relationship between Lp(a) and atherosclerotic risk.

Lifetime Exposure

Because Lp(a) concentration is often elevated from a young age, arteries may be exposed to this inherited risk factor for decades.

The duration of exposure is part of the reason early identification can be valuable.

High Lp(a) does not guarantee that disease will develop, but it can increase risk in addition to LDL cholesterol, blood pressure and other cardiovascular factors.

What Is the Connection Between Lp(a) and Aortic Valve Stenosis?

Elevated Lp(a) is associated not only with atherosclerotic cardiovascular disease but also with calcific aortic valve disease.

The aortic valve regulates blood flow from the heart's left ventricle into the aorta.

What Is Calcific Aortic Valve Disease?

Calcific aortic valve disease involves progressive changes in the valve leaflets, including thickening and calcium deposition.

When these changes significantly restrict valve opening, the condition is called aortic stenosis.

How Is Lp(a) Involved?

Genetic and epidemiological studies support a relationship between elevated Lp(a) and calcific aortic valve stenosis.

Oxidized phospholipids carried by Lp(a) may contribute to inflammatory and calcification-related processes within the valve.

However, the exact mechanisms and the extent to which lowering Lp(a) prevents valve disease remain under investigation.

What Symptoms Can Aortic Stenosis Cause?

Advanced aortic stenosis may cause shortness of breath during activity, chest discomfort, dizziness, fainting or reduced exercise tolerance.

These symptoms warrant prompt clinical assessment, especially if a heart murmur or known valve disease is present.

Does Everyone With High Lp(a) Need an Echocardiogram?

No. Elevated Lp(a) alone does not automatically mean that a person has aortic stenosis or needs routine echocardiography.

An echocardiogram may be appropriate when examination findings, symptoms or known valve disease indicate the need.

High Lp(a) can still be relevant to the clinician's overall assessment of inherited cardiovascular risk.

Should Everyone Get an Lp(a) Blood Test?

Yes. The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in all adults for atherosclerotic cardiovascular risk assessment.

This recommendation reflects the inherited nature of Lp(a) and the fact that routine cholesterol measurements may not identify the risk it represents.

Why Test Once in Adulthood?

Lp(a) generally remains relatively stable throughout adult life.

A single accurate result can therefore provide useful long-term information.

Is Lp(a) Included in an Ordinary Lipid Panel?

No. A routine lipid panel typically measures total cholesterol, LDL-C, HDL-C and triglycerides.

Lp(a) usually must be ordered separately.

Do You Need to Fast?

No. Fasting is not required for an Lp(a) measurement.

However, fasting may be requested if other laboratory tests are being performed at the same time.

Is a Genetic Test Necessary?

Not routinely. Direct measurement of Lp(a) concentration is generally sufficient for clinical risk assessment.

Routine LPA genetic sequencing or apo(a) isoform testing is not necessary for most people.

What Makes an Lp(a) Test Reliable?

The 2026 guideline recommends laboratories using methods that minimize interference from apo(a) isoform size and are traceable to appropriate reference standards.

When available, assays reporting Lp(a) particle concentration in nmol/L are preferred.

What Do Lp(a) Levels Mean?

Lp(a)-associated cardiovascular risk generally increases as concentration increases.

However, the relationship is continuous rather than a sudden transition from completely safe to dangerous at one exact number.

The 2026 guideline provides reference concentrations that help clinicians interpret the degree of inherited risk.

Below 75 nmol/L — Lower Lp(a)-Related Risk

Concentrations below approximately 75 nmol/L, or below 30 mg/dL using mass-based methods, are generally considered within a lower Lp(a)-related risk range.

This does not eliminate cardiovascular risk from LDL, diabetes, blood pressure or other causes.

75–124 nmol/L — Intermediate Range

Concentrations between 75 and 124 nmol/L fall within an intermediate range.

The guideline's population-based estimates suggest some additional risk compared with lower concentrations.

Results near clinical thresholds may sometimes warrant confirmation depending on assay quality and circumstances.

125 nmol/L or Higher — Risk-Enhancing Level

An Lp(a) concentration of at least 125 nmol/L, corresponding approximately to 50 mg/dL in guideline risk categories, is considered an important cardiovascular risk-enhancing factor.

The 2026 guideline associates this concentration with about 1.4 times the atherosclerotic cardiovascular risk of a population-median reference.

250 nmol/L or Higher — Substantially Increased Risk

At approximately 250 nmol/L, corresponding to about 100 mg/dL in the guideline's approximate categories, estimated relative cardiovascular risk is about twice that of the population-median reference.

Around 430 nmol/L — Very Marked Elevation

At approximately 430 nmol/L, corresponding to about 180 mg/dL in the guideline's reference categories, estimated relative risk may be about four times that of the reference population.

This level deserves careful assessment of other risk factors and appropriate cardiovascular prevention.

What Do Relative Risk Figures Mean?

A relative risk increase does not indicate the probability that one specific person will have a heart attack.

For example, doubling a relatively low baseline risk produces a different absolute risk than doubling an already high baseline risk.

Age, smoking, blood pressure, LDL cholesterol, diabetes, kidney disease and previous cardiovascular events strongly influence the individual's overall risk.

Lp(a) is a risk-enhancing marker, not a prediction that a cardiovascular event is certain.

Why Can't Lp(a) Be Converted Directly Between mg/dL and nmol/L?

Lp(a) is reported using two different types of laboratory measurement.

Nanomoles per liter, or nmol/L, describe molar particle concentration.

Milligrams per deciliter, or mg/dL, describe mass concentration.

Lp(a) Particles Vary in Size

The apo(a) component of Lp(a) varies substantially between individuals because of differences in its repeated structural regions.

Consequently, Lp(a) particles do not all have the same molecular mass.

A Fixed Conversion Factor Is Not Accurate

Because particle mass varies, a simple universal mathematical conversion between mg/dL and nmol/L is not reliable.

Some publications display approximate paired reference values for convenience, but these should not be used to convert an individual laboratory result as though the relationship were exact.

Why Laboratory Methods Matter

Different assays may respond differently to variations in apo(a) structure.

This can affect the comparability of results from different laboratories.

When possible, use an assay standardized to recognized reference materials and designed to minimize isoform-related measurement bias.

How Should You Interpret Your Result?

Use the units reported by the laboratory and compare the value with appropriate reference thresholds for that measurement method.

Do not multiply or divide by a single number to create a supposedly exact conversion.

When results from different laboratories appear inconsistent, a healthcare professional can determine whether repeat testing using a suitable assay is appropriate.

Does High Lp(a) Cause Symptoms?

Usually not.

Elevated Lp(a) generally causes no recognizable symptoms, even when concentration is substantially increased.

It is therefore possible to have high Lp(a), normal exercise tolerance and no cardiovascular complaints.

Symptoms may arise if a person develops a related cardiovascular condition, such as coronary artery disease, peripheral artery disease or aortic stenosis.

However, the symptoms belong to the underlying disease rather than serving as a reliable indication of Lp(a) concentration.

Measurement is necessary to know whether Lp(a) is elevated.

Can High Lp(a) Run in Families?

Yes. Because Lp(a) is largely genetically determined, elevated concentrations often occur in biological relatives.

Family testing can identify people who may otherwise remain unaware of an important inherited cardiovascular risk factor.

Who Should Be Offered Family Testing?

The 2026 ACC/AHA guideline recommends cascade testing of first-degree relatives when high Lp(a), premature atherosclerotic cardiovascular disease or familial hypercholesterolemia is present.

First-degree relatives include biological parents, siblings and children.

Does Every Relative Have the Same Lp(a)?

No. Relatives can inherit different combinations of genetic variants, resulting in different Lp(a) concentrations.

Individual measurement is more reliable than assuming everyone in the family has the same result.

What About Children?

Because Lp(a) is inherited and present from early life, testing can be appropriate in children from affected families.

The timing should be discussed with a pediatric clinician, especially where there is premature cardiovascular disease, familial hypercholesterolemia or markedly elevated Lp(a) in a close relative.

Why Does Family History Matter?

A family history of premature heart attack, stroke or aortic stenosis can increase concern about inherited cardiovascular risk.

However, Lp(a) may be elevated even when no family member has yet experienced a recognizable cardiovascular event.

Can Diet or Exercise Lower Lp(a)?

Ordinary diet, exercise and weight loss usually have little effect on Lp(a) concentration itself.

This is an important distinction from LDL cholesterol and triglycerides, which often respond more substantially to nutritional and lifestyle changes.

However, it would be a mistake to conclude that healthy habits do not matter when Lp(a) is elevated.

Why Nutrition Still Matters

A nutritious dietary pattern can reduce LDL cholesterol, improve blood pressure and support metabolic health.

These benefits reduce modifiable cardiovascular risk even if Lp(a) remains unchanged.

Why Exercise Still Matters

Regular physical activity supports cardiovascular fitness, glucose regulation, blood pressure and body composition.

These effects remain valuable for someone with inherited Lp(a) elevation.

Why Smoking Cessation Matters

Smoking increases cardiovascular risk independently of Lp(a).

Stopping smoking is therefore particularly important when inherited risk is already elevated.

Does Weight Loss Normalize Lp(a)?

Not reliably. Appropriate weight reduction may improve triglycerides, blood sugar and blood pressure, but it should not be promised as a method for normalizing inherited Lp(a).

With high Lp(a), lifestyle improvement is primarily about reducing the cardiovascular consequences of inherited risk, not expecting the inherited marker itself to disappear.

What Should You Do if Your Lp(a) Is High?

The next step is to evaluate the complete cardiovascular risk profile and identify opportunities for prevention.

The 2026 guideline recommends early, intensive management of modifiable cardiovascular risk factors in people with elevated Lp(a).

Review LDL Cholesterol

LDL is a major modifiable atherosclerotic risk factor.

When Lp(a) is elevated, a clinician may recommend earlier or more intensive LDL-lowering treatment depending on the individual's overall risk.

Consider ApoB and Non-HDL Cholesterol

These measurements may clarify the broader burden of atherogenic particles, particularly when triglycerides or metabolic conditions complicate the lipid profile.

Control Blood Pressure

Persistent hypertension increases cardiovascular risk and should be managed through evidence-based lifestyle changes and medication when appropriate.

Assess Blood Sugar and Kidney Function

Diabetes, chronic kidney disease and other metabolic conditions can add to inherited cardiovascular risk.

Appropriate testing and treatment can identify and address these factors.

Review Family History

Premature cardiovascular events or aortic stenosis among biological relatives may strengthen the case for additional risk evaluation.

Consider Coronary Artery Calcium Testing When Appropriate

Coronary artery calcium scoring may help refine risk in selected adults when primary-prevention treatment decisions remain uncertain.

However, a calcium score of zero does not completely eliminate the lifetime risk associated with high Lp(a), particularly in younger people or those with noncalcified plaque.

Not everyone with high Lp(a) requires coronary calcium imaging.

Develop a Risk-Based Treatment Plan

The objective is to reduce the combined cardiovascular burden rather than attempting to normalize Lp(a) through an unproven intervention.

Are There Medicines That Lower Lp(a)?

There are currently limited clinically available options for lowering Lp(a), and treatments differ in their demonstrated effects on cardiovascular outcomes.

It is important to distinguish medications that reduce LDL-related cardiovascular risk from those specifically being developed to lower Lp(a).

Statins

Statins are effective LDL-lowering medications with strong evidence for reducing cardiovascular events in appropriate populations.

They generally do not reduce Lp(a) and may modestly increase its concentration in some individuals.

However, a small Lp(a) increase is not a reason to stop a statin when its established cardiovascular benefits are important.

Ezetimibe

Ezetimibe reduces intestinal cholesterol absorption and can help lower LDL cholesterol.

It is not an established treatment for substantially lowering Lp(a), but may be useful for managing the broader lipid-risk profile.

PCSK9 Inhibitors

PCSK9-targeting therapies lower LDL cholesterol substantially and can also reduce Lp(a) modestly, often by approximately 15%–30% depending on the treatment and population.

Monoclonal antibody treatments such as evolocumab and alirocumab have demonstrated cardiovascular benefits in appropriate high-risk populations.

However, they are not currently approved specifically for Lp(a) reduction, and their clinical benefits cannot be attributed exclusively to the change in Lp(a).

Lipoprotein Apheresis

Lipoprotein apheresis is a specialized procedure that removes certain lipoproteins from the circulation.

It can reduce LDL and Lp(a), but it is resource-intensive and used in selected high-risk patients rather than as a routine treatment.

In the United States, specific FDA-approved apheresis indications include certain patients with familial hypercholesterolemia, documented cardiovascular disease and elevated Lp(a) despite maximally tolerated lipid-lowering therapy.

Niacin

High-dose nicotinic acid can lower Lp(a) to some degree, but clinical trials have not established cardiovascular outcome benefits sufficient to support routine use for this purpose.

High-dose niacin can also cause adverse effects involving glucose regulation, liver function, flushing and other systems.

It is not recommended as a routine self-directed treatment for elevated Lp(a).

What About New Lp(a)-Targeted Drugs?

Several experimental therapies are being developed to reduce Lp(a) production more specifically.

These include antisense oligonucleotide and small interfering RNA technologies that act on pathways involved in apolipoprotein(a) production.

Pelacarsen

Pelacarsen is an antisense oligonucleotide designed to reduce production of apolipoprotein(a).

Although it lowered Lp(a), the phase 3 Lp(a)HORIZON cardiovascular outcomes trial did not meet its primary endpoint of reducing cardiovascular events, according to results announced on September 4, 2026.

This is an important example of why lowering a biomarker does not automatically establish that a particular therapy prevents heart attacks or strokes.

Further analysis of the trial may provide additional information about the findings.

Olpasiran

Olpasiran is an investigational small interfering RNA therapy designed to reduce apolipoprotein(a) production.

Clinical studies have shown substantial Lp(a) reductions, but the definitive question is whether treatment improves cardiovascular outcomes in adequately designed trials.

Outcome research remains important before broad clinical use can be justified.

Lepodisiran and Other Investigational Therapies

Lepodisiran and several other agents are also being studied for their ability to substantially lower Lp(a).

Promising concentration reductions do not by themselves establish long-term safety or prevention of cardiovascular events.

Are Lp(a)-Specific Drugs Approved?

As of November 2026, there is no widely approved drug specifically indicated for selective Lp(a) lowering and proven through completed outcome trials to prevent cardiovascular events solely by targeting Lp(a).

Existing lipid-lowering treatments remain important because they reduce established cardiovascular risks, even when inherited Lp(a) remains elevated.

Can High Lp(a) Be Reduced Naturally?

There is no established food, herb or ordinary supplement that reliably normalizes genetically elevated Lp(a) or has demonstrated prevention of cardiovascular events through specific Lp(a) reduction.

However, whole-person cardiovascular support remains valuable because inherited risk acts alongside modifiable factors.

Follow a Heart-Healthy Food Pattern

Mediterranean-style and DASH-style eating patterns emphasize vegetables, fruit, legumes, whole grains, suitable proteins and unsaturated fats.

These approaches support LDL cholesterol, blood pressure and other cardiovascular markers.

Improve Dietary Fat Quality

Replacing some saturated-fat-rich foods with appropriate unsaturated-fat sources can lower LDL cholesterol in many people.

This can reduce atherosclerotic risk even if Lp(a) concentration does not change.

Include Appropriate Soluble Fiber

Oats, barley, legumes and viscous psyllium can support LDL reduction through established nutritional mechanisms.

Their benefit should not be presented as a proven direct reduction in inherited Lp(a).

Maintain Regular Physical Activity

Aerobic activity and resistance training improve cardiovascular fitness, metabolic health and other risk factors.

They remain important regardless of Lp(a) level.

Address Metabolic Health

When diabetes, insulin resistance or excess visceral fat is present, appropriate treatment can improve additional cardiovascular risks.

Avoid Smoking and Protect Sleep

Smoking cessation provides substantial cardiovascular benefit. Healthy sleep and evaluation of relevant sleep disorders are also important.

Manage Blood Pressure

Blood-pressure control is particularly valuable when inherited atherosclerotic risk is elevated.

Appropriate lifestyle measures and prescription treatment should be used according to clinical need.

Natural prevention is meaningful even when the inherited Lp(a) number remains unchanged. Its purpose is to improve the cardiovascular environment in which that risk factor operates.

Where Does Total Health Secrets Cardiovascular Support Fit?

Total Health Secrets offers products intended to support cardiovascular nutrition, antioxidant function, dietary fiber intake and cellular health.

For elevated Lp(a), the appropriate role of these products must be distinguished from targeted treatment of the inherited lipoprotein itself.

No reviewed Total Health Secrets product has been established through high-quality clinical trials as a treatment that reliably lowers Lp(a) or prevents Lp(a)-related cardiovascular events.

However, selected products may complement a complete nutritional program when there is a specific need.

Lipid-Related Antioxidant Support — Deltanol

Deltanol from Premier Research Labs contains annatto-derived tocotrienols, compounds belonging to the vitamin E family.

The current ingredient information identifies 99 milligrams of tocotrienols from DeltaGold, consisting predominantly of delta-tocotrienols with a smaller gamma-tocotrienol component.

Tocotrienols have been investigated for antioxidant and lipid-related biological effects.

However, evidence does not establish that Deltanol lowers genetically elevated Lp(a), removes arterial plaque or prevents cardiovascular events.

It may be considered as targeted antioxidant nutritional support when appropriate, but it should not be presented as a substitute for established cardiovascular risk reduction.

Broad Botanical Cardiovascular Support — Cardio-ND

Cardio-ND from Premier Research Labs contains a fermented botanical blend including hawthorn berry, green tea extract, turmeric, cinnamon, bear garlic leaf, garlic bulb extract and cayenne.

The product is positioned for broad cardiovascular and circulatory nutritional support.

However, these ingredients do not establish that the finished formula reduces Lp(a), prevents calcific aortic stenosis or reverses atherosclerosis.

Cardio-ND should therefore be considered according to its intended nutritional purpose, not as a treatment for an inherited lipoprotein abnormality.

Heart Muscle and Cellular Energy Support — CoQ-10

CoQ-10 from Premier Research Labs provides 100 milligrams of coenzyme Q10 in the ubiquinone form per capsule.

CoQ10 participates in mitochondrial energy production and normal cellular antioxidant processes.

It can be considered within a cardiovascular nutritional program focused on cellular energy support.

However, CoQ10 is not an established treatment for high Lp(a), and it has not been proven to prevent aortic stenosis or Lp(a)-related cardiovascular events.

It may also interact with warfarin.

Dietary Fiber and Digestive Nutrition — Galactan

Galactan from Premier Research Labs contains larch-derived arabinogalactan.

The current supplement facts identify 6 grams of dietary fiber per two-tablespoon serving.

Galactan may contribute to fiber intake and support intestinal microbial fermentation.

However, its effects should not be equated with the established LDL-lowering evidence for viscous psyllium, and there is no reliable evidence that it corrects high Lp(a).

It fits more appropriately within digestive and dietary-fiber nutritional support.

Plant-Based Nutritional Support — Premier Greens Powder

Premier Greens Powder contains plant-derived ingredients including organic barley grass, oat grass, kale and chlorella.

The formula may complement a varied diet when plant-food intake is inconsistent.

However, it should not replace whole vegetables, fruit, legumes and whole grains.

It is not an established treatment for lowering Lp(a), LDL or ApoB, and claims involving blood alkalinity should not be treated as evidence of cardiovascular protection.

Should You Take Several Supplements to Lower Lp(a)?

Not automatically. Combining antioxidant, botanical and nutritional products has not been shown to reliably correct inherited Lp(a) elevation.

Multiple supplements can also increase cost, side effects and medication-interaction concerns.

More effective priorities include appropriate LDL reduction, blood-pressure control, diabetes management, smoking cessation and evaluation of other cardiovascular risks.

Targeted supplementation should support a defined nutritional purpose while recognizing that inherited Lp(a) risk requires an evidence-based cardiovascular prevention strategy.

Explore the Heart, Blood Pressure, Cholesterol & Circulation collection for relevant nutritional-support options.

Should People With High Lp(a) Take Aspirin?

Not automatically.

Some research suggests that selected people with elevated Lp(a) may obtain cardiovascular benefits from aspirin, but the evidence does not justify routine aspirin use solely because Lp(a) is high.

Aspirin can increase the risk of gastrointestinal and other bleeding.

For someone who has already experienced a heart attack or certain ischemic strokes, antiplatelet treatment may be recommended for established reasons independent of Lp(a).

For primary prevention, the balance of cardiovascular benefit and bleeding risk requires individualized assessment.

Do not begin daily aspirin or replace prescribed antiplatelet therapy based solely on an Lp(a) result.

How Often Should Lp(a) Be Rechecked?

Because Lp(a) is largely inherited and usually remains stable, one accurate adult measurement is generally sufficient.

However, repeat testing can be appropriate in selected circumstances.

Intermediate or Borderline Results

A result near a risk threshold may justify confirmation, particularly if different laboratories use different assays or units.

Conditions That May Affect Lp(a)

Kidney disease, certain thyroid or liver conditions, pregnancy, menopausal changes and some medical treatments can influence Lp(a) measurements.

Repeat testing may be useful if these circumstances materially change.

When Starting an Lp(a)-Targeting Therapy

In research settings or selected specialist treatment situations, serial testing may be necessary to assess the effects of an intervention.

Why Repeated Routine Testing Is Usually Unnecessary

For most people, repeating Lp(a) every few months does not provide meaningful additional information.

It is usually more useful to follow modifiable markers such as LDL-C, non-HDL-C, ApoB when indicated, blood pressure and glucose control.

A Practical 14-Step Strategy for Elevated Lp(a)

Step 1 — Obtain an Accurate Lp(a) Measurement

Have Lp(a) measured at least once in adulthood using an appropriate laboratory method.

Step 2 — Check the Units

Determine whether the result is reported in nmol/L or mg/dL, and avoid using an assumed exact conversion.

Step 3 — Understand the Risk Category

Review whether the result falls in a lower, intermediate, elevated or markedly elevated range according to the applicable guideline.

Step 4 — Review Family History

Consider premature heart attack, stroke, aortic stenosis and diagnosed lipid disorders in biological relatives.

Step 5 — Discuss Family Screening

When high Lp(a) or premature cardiovascular disease is present, first-degree relatives may benefit from testing.

Step 6 — Evaluate LDL Cholesterol

Identify whether LDL is above an appropriate treatment goal and whether more intensive reduction is needed.

Step 7 — Consider ApoB and Non-HDL Cholesterol

Use these measurements when they provide additional information about atherogenic particle exposure.

Step 8 — Control Blood Pressure

Maintain an appropriate blood-pressure pattern through nutrition, activity, monitoring and treatment when indicated.

Step 9 — Assess Blood Sugar and Kidney Function

Identify diabetes, chronic kidney disease and other conditions that can add to inherited cardiovascular risk.

Step 10 — Follow a Heart-Healthy Dietary Pattern

Emphasize vegetables, legumes, fruit, whole grains, suitable proteins and unsaturated fats.

Step 11 — Maintain Movement and Avoid Nicotine

Use sustainable aerobic and resistance exercise, and avoid smoking and other nicotine exposure.

Step 12 — Choose Supplements for Specific Needs

Use nutritional products according to their established purpose without expecting them to normalize inherited Lp(a).

Step 13 — Discuss Evidence-Based Treatment

Depending on risk, appropriate LDL-lowering medication or specialist evaluation may provide important protection.

Step 14 — Monitor the Risks You Can Change

Follow LDL-C, blood pressure, diabetes control and other relevant factors over time rather than repeatedly checking an inherited marker that generally remains stable.

When Should High Lp(a) Receive Medical Evaluation?

Elevated Lp(a) is not usually an emergency, but it can be an important reason for more careful cardiovascular assessment.

Seek appropriate medical guidance when:

• Lp(a) is 125 nmol/L or higher, or approximately 50 mg/dL or higher using a suitable mass-based assay.
• Lp(a) is markedly elevated, particularly at or above approximately 250 nmol/L.
• There is a family history of premature heart attack or stroke.
• Familial hypercholesterolemia or another inherited lipid disorder is suspected.
• A close relative has high Lp(a) or premature aortic stenosis.
• LDL cholesterol remains above an appropriate treatment goal.
• Diabetes, kidney disease or hypertension adds to cardiovascular risk.
• Coronary artery disease, ischemic stroke or peripheral artery disease is already present.
• Symptoms or examination findings suggest aortic valve disease.
• There is uncertainty about how to interpret different laboratory units or assay results.

High Lp(a) alone does not establish the presence of plaque or aortic stenosis. The need for additional testing depends on the complete clinical picture.

Chest pain, sudden severe shortness of breath, one-sided weakness, difficulty speaking or other possible heart-attack or stroke symptoms require immediate emergency care regardless of Lp(a) concentration.

Frequently Asked Questions About Lipoprotein(a)

What is lipoprotein(a) in simple terms?

Lp(a) is a mostly inherited cholesterol-carrying particle that can increase cardiovascular risk when its concentration is elevated.

Is Lp(a) the same as LDL cholesterol?

No. Lp(a) resembles LDL but contains an additional protein called apolipoprotein(a), giving it distinct properties and inherited risk characteristics.

Why is Lp(a) dangerous?

Elevated Lp(a) contributes to atherosclerotic cardiovascular risk and is associated with calcific aortic valve stenosis. The degree of risk also depends on other cardiovascular factors.

Does everyone need an Lp(a) blood test?

Yes. The 2026 ACC/AHA guideline recommends at least one Lp(a) measurement in every adult.

Is Lp(a) included in a standard cholesterol test?

No. It usually requires a separately ordered blood test.

Do you need to fast for Lp(a) testing?

No. Fasting is not required for an Lp(a) measurement, although it may be requested for other simultaneous tests.

What is considered high Lp(a)?

The 2026 guideline considers 125 nmol/L or higher, or approximately 50 mg/dL or higher in mass-based testing, an important cardiovascular risk-enhancing level.

Is Lp(a) of 250 nmol/L high?

Yes. It is substantially elevated and is associated with approximately twice the atherosclerotic cardiovascular risk of a population-median reference in guideline estimates.

Can you convert Lp(a) from mg/dL to nmol/L?

Not precisely using one universal factor. Particle sizes vary between individuals, so mass and particle concentration are not directly interchangeable.

Can Lp(a) be high when LDL is normal?

Yes. Lp(a) is largely inherited and can be elevated despite favorable LDL-C, triglycerides or lifestyle habits.

Is high Lp(a) genetic?

Yes. Lp(a) concentration is predominantly influenced by inherited variants affecting the LPA gene.

Should my family get tested if my Lp(a) is high?

First-degree biological relatives may benefit from cascade testing, particularly when high Lp(a), familial hypercholesterolemia or premature cardiovascular disease is present.

Does high Lp(a) cause symptoms?

Usually not. High Lp(a) is generally silent and can only be identified through blood testing.

Can Lp(a) cause aortic stenosis?

Elevated Lp(a) is causally associated with calcific aortic valve disease and increased risk of aortic stenosis, although not everyone with high Lp(a) develops valve disease.

Does high Lp(a) mean I have arterial plaque?

No. High Lp(a) identifies increased risk but does not independently establish that plaque is already present.

Can diet lower Lp(a)?

Ordinary diet generally has little effect on genetically elevated Lp(a). However, nutritious eating can improve LDL and other modifiable cardiovascular risks.

Does exercise lower Lp(a)?

Exercise usually does not substantially lower Lp(a) concentration, but it supports cardiovascular fitness, blood pressure and metabolic health.

Does vitamin C lower Lp(a)?

There is no reliable evidence that routine vitamin C supplementation meaningfully reduces inherited Lp(a) and prevents cardiovascular events.

Can niacin lower Lp(a)?

High-dose niacin can reduce Lp(a) in some individuals, but clinical evidence does not support routine use for preventing cardiovascular events, and adverse effects are a concern.

Can CoQ10 lower Lp(a)?

CoQ10 supports normal cellular energy metabolism but is not an established Lp(a)-lowering treatment.

Do statins lower Lp(a)?

Generally not. Statins may leave Lp(a) unchanged or modestly increase it, but their LDL-lowering and cardiovascular benefits remain important when treatment is indicated.

Do PCSK9 inhibitors lower Lp(a)?

They can reduce Lp(a) modestly while substantially lowering LDL-C. However, they are not specifically approved as Lp(a)-targeting treatments.

What happened in the pelacarsen trial?

In September 2026, the phase 3 Lp(a)HORIZON trial was reported not to have met its primary cardiovascular-outcomes endpoint, despite lowering Lp(a).

Is there a cure for high Lp(a)?

There is currently no established cure for inherited Lp(a) elevation. Management focuses on cardiovascular risk reduction, with specialized treatments and investigational therapies available in selected circumstances.

How often should Lp(a) be checked?

One accurate measurement is generally sufficient because levels are relatively stable. Repeat testing may be appropriate in selected clinical situations.

Can someone with high Lp(a) live a long, healthy life?

Yes. High Lp(a) increases risk but does not determine an individual's future. Effective management of LDL, blood pressure, smoking, diabetes and other factors can provide meaningful cardiovascular protection.

A Better Definition of Lipoprotein(a) Support

Lipoprotein(a) represents a different kind of cardiovascular challenge from ordinary dietary cholesterol or many triglyceride abnormalities.

It is a largely inherited lipoprotein whose concentration may remain elevated throughout life, even in someone with healthy eating habits, regular exercise and favorable body composition.

High Lp(a) can contribute to atherosclerotic cardiovascular risk and is also associated with calcific aortic valve disease.

This does not mean an individual with elevated Lp(a) is destined to develop heart disease. Risk depends on the inherited concentration and the other factors affecting the heart and blood vessels over time.

Because lifestyle changes usually have little effect on Lp(a) itself, the objective should not be to force the number down through increasingly restrictive diets or multiple supplements.

Instead, the most useful strategy begins with accurate testing, appropriate interpretation and family awareness.

From there, attention can turn to LDL cholesterol, blood pressure, glucose regulation, kidney function, smoking exposure and other modifiable risks.

Heart-healthy nutrition, physical activity, adequate sleep and sustainable metabolic health remain essential even when the inherited Lp(a) result does not change.

Targeted nutritional products may complement these foundations for specific purposes, but they should not be presented as proven treatments for inherited Lp(a) elevation.

Medical lipid-lowering treatment may provide important additional protection, especially in people with established atherosclerotic disease or substantial overall risk.

New Lp(a)-targeted therapies remain an important research area, but clinical benefits must be established through rigorous cardiovascular-outcomes trials rather than assumed from lower laboratory values.

A better definition of lipoprotein(a) support is recognizing inherited cardiovascular risk early, managing the factors that can be improved and using proven prevention and treatment to protect long-term heart, artery and valve health.

For a broader explanation of cholesterol, blood pressure, circulation and cardiovascular risk, continue reading our pillar guide: Heart Health Explained: Blood Pressure, Cholesterol, Circulation and Cardiovascular Risk.

References and Further Reading

1. American Heart Association and American College of Cardiology. 2026 Dyslipidemia Guideline — Top Things to Know. Updated March 13, 2026. Reviews Lp(a) testing, inherited risk, treatment priorities and current cardiovascular prevention recommendations.
2. American Heart Association and American College of Cardiology. 2026 Guideline on the Management of Dyslipidemia. Full clinical guideline, including Lp(a) measurement, family screening, risk interpretation and management.
3. American Heart Association. Lipoprotein(a). Patient education explaining inherited risk, once-in-adulthood testing and cardiovascular implications.
4. American College of Cardiology. An Update on Lipoprotein(a): Testing, Treatment, and Guideline Recommendations. Discusses testing methods, interpretation and the limitations of converting units.
5. European Atherosclerosis Society. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A Consensus Statement. Reviews genetic determinants, clinical risk, aortic valve disease and measurement issues.
6. National Lipid Association. Lipoprotein(a) Management Simplified. Published September 25, 2026. Practical guidance on inherited risk, testing, family screening and treatment limitations.
7. National Lipid Association. Top Line Results From the Phase 3 Lp(a)HORIZON Trial. Published September 14, 2026. Reviews the reported failure to meet the primary cardiovascular-outcomes endpoint despite Lp(a) reduction.
8. Novartis. Lp(a)HORIZON Phase III Topline Results. September 4, 2026. Primary sponsor announcement.
9. Centers for Disease Control and Prevention. About Lipoprotein(a). Explains family history, cardiovascular risk and the importance of testing.
10. National Heart, Lung, and Blood Institute. Atherosclerosis. Reviews arterial plaque and cardiovascular complications.
11. American Heart Association. Life's Essential 8. Cardiovascular health framework including nutrition, activity, sleep, nicotine avoidance, weight, blood lipids, blood sugar and blood pressure.
12. National Center for Complementary and Integrative Health. High Cholesterol and Natural Products. Reviews evidence limitations and safety considerations for nutritional supplements.
13. Total Health Secrets. Deltanol. Current tocotrienol ingredients and antioxidant nutritional positioning.
14. Total Health Secrets. Cardio-ND. Current fermented botanical cardiovascular-support formula.
15. Total Health Secrets. CoQ-10. Current coenzyme Q10 formulation and cellular-energy nutritional positioning.
16. Total Health Secrets. Galactan. Current larch arabinogalactan fiber information.
17. Total Health Secrets. Premier Greens Powder. Current plant-derived nutritional ingredients.

Educational Disclaimer: This article provides general educational information and does not replace individualized medical advice, diagnosis or treatment. Lp(a) results should be interpreted using the laboratory's reported units and a suitable assay, together with LDL-C, ApoB when indicated, blood pressure, diabetes, kidney function, smoking status, family history and established cardiovascular disease. An elevated Lp(a) concentration does not independently diagnose arterial plaque, aortic stenosis or an inevitable cardiovascular event. Lifestyle changes generally do not substantially lower inherited Lp(a), but they can improve other important cardiovascular risks. Dietary supplements are not established treatments for elevated Lp(a) and may interact with prescription medicines, anticoagulants and antiplatelet therapies. Do not begin aspirin, high-dose niacin or other treatments, or discontinue prescribed lipid-lowering medication, without appropriate medical advice. Chest pain, sudden severe breathlessness, one-sided weakness, difficulty speaking or other possible heart-attack or stroke symptoms require immediate emergency care.